Holen Sie sich die Stockscreener-App
34.04
0.90%
-0.31
Vorhandelsmarkt:
34.20
0.16
+0.47%
Schlusskurs vom Vortag:
$34.35
Offen:
$34.3
24-Stunden-Volumen:
448.61K
Relative Volume:
0.38
Marktkapitalisierung:
$2.44B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-299.62M
KGV:
-7.2986
EPS:
-4.6639
Netto-Cashflow:
$-241.73M
1W Leistung:
-8.79%
1M Leistung:
-15.47%
6M Leistung:
+19.61%
1J Leistung:
+73.41%
1-Tages-Spanne:
$33.91
$34.88
1-Wochen-Bereich:
$32.81
$37.44
52-Wochen-Spanne:
$18.76
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Firmenname
Vera Therapeutics Inc
Sektor
Branche
Telefon
650-770-0077
Adresse
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
34.04 | 2.47B | 0 | -299.62M | -241.73M | -4.6639 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-10-16 | Eingeleitet | BofA Securities | Buy |
| 2025-08-04 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2025-01-28 | Eingeleitet | Goldman | Buy |
| 2024-11-21 | Eingeleitet | Wells Fargo | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Eingeleitet | Raymond James | Outperform |
| 2023-11-10 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-16 | Eingeleitet | Guggenheim | Buy |
| 2023-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-04 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-19 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $86 - Moomoo
Vera Therapeutics (VERA) Is Down 11.6% After Wider Q1 Loss Highlights Rising Cost Burden - Sahm
VERA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
VERA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Vera Therapeutics, Inc.Class A Common Stock (NQ: VERA - FinancialContent
UBS Group AG Boosts Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Why (VERA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
T. Rowe Price (VERA) reports 4.57M shares, 6.4% ownership (Amendment) - Stock Titan
Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $91 - Moomoo
Vera Therapeutics president and CEO sells $679,747 in stock By Investing.com - Investing.com Canada
Vera Therapeutics president and CEO sells $679,747 in stock - Investing.com UK
Vera Therapeutics (VERA) CEO sells 18,500 shares under 10b5-1 plan - Stock Titan
H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $110 - Moomoo
[144] Vera Therapeutics, Inc. SEC Filing - Stock Titan
Vera Therapeutics (VERA) Receives a Buy from Guggenheim - The Globe and Mail
TradingKey - TradingKey
Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $56 - Moomoo
The Bull Case For Vera Therapeutics (VERA) Could Change Following Atacicept’s FDA Priority Review And Ramp-Up - Yahoo! Finance Canada
A Look At Vera Therapeutics (VERA) Valuation After FDA Priority Review For Atacicept In IgA Nephropathy - Sahm
Does Vera’s Widening Quarterly Net Loss Reframe the Bull Case for Vera Therapeutics (VERA)? - Sahm
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Vera Therapeutics announces inducement grants under Nasdaq listing rule 5635(C)(4) - TradingView
Ten new hires get Vera stock awards tied to 60,375 shares - Stock Titan
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $73 - Moomoo
Vera Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Vera Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Vera Therapeutics (VERA) ramps spending as atacicept nears key FDA decision - Stock Titan
LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $90 - Moomoo
Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vera Therapeutics, Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Kidney disease drug gets July 7 FDA date as Vera readies launch - Stock Titan
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - marketscreener.com
[8-K] Vera Therapeutics, Inc. Reports Material Event - Stock Titan
Press Release: Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - Moomoo
Vera Therapeutics faces earnings test ahead of FDA verdict - Investing.com UK
Vera Therapeutics faces earnings test ahead of FDA verdict By Investing.com - Investing.com South Africa
Understanding Momentum Shifts in (VERA) - Stock Traders Daily
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference - The Manila Times
Vera Therapeutics to present May 13 at Bank of America health conference - Stock Titan
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight - GlobeNewswire Inc.
Pictet Asset Management Holding SA Cuts Stake in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics (VERA) to Release Earnings on Tuesday - MarketBeat
HC Wainwright & Co. Maintains Vera Therapeutics (VERA) Buy Recommendation - MSN
Finanzdaten der Vera Therapeutics Inc-Aktie (VERA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):